FHL2 and cancer: The mechanism proposed here could explain (i) why it is possible, when MSCs differentiate in osteoprogenitors, to observe the protein FHL2 in MSCs still engaged in the differentiation phase, and (ii) why, in a healthy differentiated or pre-differentiated breast (cancer) tissue, the cells are devoid of FHL2.